TD Cowen analyst Charles Rhyee initiated coverage of Option Care Health (OPCH) with a Hold rating and $30 price target Option is the leading home and alternate site infusion provider with exposure to specialty and a balance sheet that supports capital deployment, the analyst tells investors in a research note. The firm thinks the company can hit its long-term growth targets, but says this is already reflected in consensus estimates. TD cites this and a lack of obvious share catalysts for the Hold rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health Amends Credit Agreement for Refinancing
- Option Care Health: Strategic Positioning and Growth Potential Drive Buy Rating
- Option Care Health up 5% at $29 per share following positive Barron’s note
- Option Care Health shares ‘undervalued’, says Barron’s
- Option Care Health Appoints New CFO Meenal Sethna